Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.24), $0.08 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $16.31 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.